SMAD2 and glioblastoma: Consistent with our predictions, inhibiting TGFBR2 blocked SMAD2/3 signaling in TMZ-insensitive GBM cells, decreased self-renewal capacity (Fig. 3e, g) and restored sensitivity to TMZ treatment (Fig. 3f, h).